Paclitaxel - Beigene/Celgene Corporation
Alternative Names: ABI-007; ABRAXANE; Abraxane; ABRAXUS; Albumin-bound paclitaxel - Celgene Corporation; Coraxane; Coroxane; Nab-Paclitaxel; Systemic nanoparticle albumin-bound paclitaxelLatest Information Update: 06 Dec 2024
Price :
$50 *
At a glance
- Originator Abraxis BioScience
- Developer Abraxis BioScience; AstraZeneca; Australian and New Zealand Urogenital and Prostate Cancer Group; BeiGene; Big Ten Cancer Research Consortium; Biotoscana; Cambridge University Hospitals; Cancer Research UK; Celgene Corporation; Columbia University; Eli Lilly and Company; Emory University; Fondazione Sandro Pitigliani; Genentech; Institut fuer Frauengesundheit; M. D. Anderson Cancer Center; Merck Sharp & Dohme; National Cancer Institute (USA); NCIC Clinical Trials Group; New York University School of Medicine; Oncosur; PrECOG; Southeastern Gynecologic Oncology; Taiho Pharmaceutical; University of California, Davis; University of Iowa; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine
- Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Breast cancer; Gastric cancer; Non-small cell lung cancer; Pancreatic cancer
- Registered Squamous cell cancer
- Phase II Biliary cancer; Cholangiocarcinoma; Colorectal cancer; Head and neck cancer; HER2 negative breast cancer; Malignant melanoma; Oesophageal cancer; Small cell lung cancer; Urogenital cancer
- Phase I/II Multiple myeloma; Solid tumours
- No development reported Bladder cancer; Ovarian cancer; Prostate cancer
- Discontinued Coronary artery restenosis; Peripheral arterial disorders; Vascular restenosis
Most Recent Events
- 06 Dec 2024 Washington University School of Medicine completes the phase II APA trial in Head and neck cancer (Combination therapy, Late-stage disease) in USA (IV) (NCT02573493)
- 18 Jan 2024 Efficacy and adverse event data from the phase II ALPACA trial in Pancreatic cancer presented at the 2024 Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
- 15 Dec 2023 ORIC Pharmaceuticals terminates a phase I trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA (PO) due to IND withdrawal (NCT03928314)